Search results
Results from the WOW.Com Content Network
Eli Lilly's stock rose 9% in premarket trading before the bell on Friday. The new decision comes after a lawsuit filed by compounders forced the FDA to announce it was reviewing its original ...
Eli Lilly missed Wall Street's revenue expectations in its third quarter earnings released Wednesday morning, which sent shares down more than 6%.The drugmaker also slashed its profit guidance and ...
On Dec. 19, the FDA said off-brand versions of the Eli Lilly wight loss drug must be pulled off the market. ... Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at ...
Bad news for Novo Nordisk (NYSE: NVO) Friday was good news for Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX), its two main rivals in the field of weight loss drugs.This morning ...
The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as glucagon-like peptide-1 (GLP-1) receptor agonists, blockbuster drugs such as ...
On Monday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic ...
Shares of Eli Lilly (NYSE: LLY) were sinking 6.3% lower as of 11:11 a.m. ET on Wednesday. The sharp decline came after the big drugmaker announced its third-quarter results before the market opened.
Eli Lilly's revenue grows by 20%, but falls short of estimates Eli Lilly didn't have a bad quarter, but when perfection is priced into a stock, anything less than glorious results can end up ...